**Lisdexamfetamine**

Traffic light classification- AMBER 1
Information sheet for Primary Care Prescribers

**Indication**
Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 17 who are under the care of a Consultant Psychiatrist as part of a comprehensive treatment program when response to previous methylphenidate treatment is considered clinically inadequate.

**Any patient groups to be excluded from shared care**
Patients > 18 years old – classified as Red in Nottinghamshire
Children < 6 years old – unlicensed, not recommended by NICE

**Therapeutic Summary**
Pharmacologically inactive prodrug. After oral administration lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed to dexamfetamine.
Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action of amphetamine in ADHD is not fully established, however it is thought to be due to its ability to block the reuptake of noradrenaline and dopamine into the presynaptic neuron and increase the release of these monoamines into the extra neuronal space.

**Medicines Initiation**
NICE guidance (2018), suggests prescribing lisdexamfetamine as second line pharmacological treatment of children aged 5 years and over who have had a 6-week trial of methylphenidate at an adequate dose and not derived enough benefit in terms of reduced ADHD symptoms and associated impairment. Treatment with lisdexamfetamine should only be initiated by a specialist (e.g. psychiatrist or specialist community paediatrician) with expertise in ADHD following a comprehensive assessment and diagnosis. NICE recommend that GPs should continue prescribing and monitoring medication treatment under shared care arrangements. Use in combination with atomoxetine is felt to be clinically appropriate

**Products available**
Lisdexamfetamine hard capsules (Elvanse), 20mg, 30mg, 40mg, 50mg, 60mg, 70mg (£54.62, £58.24, £62.82, £68.60, £75.18, £83.16 respectively).

**Dosages and route of administration**
Starting dose is 30mg taken once daily (orally) in the morning. When in the judgement of the clinician a lower initial dose is appropriate, patients may begin treatment with 20mg once daily in the morning. Afternoon doses should be avoided because of the potential for insomnia. The dose may be increased by 10mg or 20 mg increments, at approximately weekly intervals. Lisdexamfetamine should be administered orally at the lowest effective dosage. The maximum recommended dose is 70mg/day; higher doses have not been studied. The medication may be swallowed whole, or the capsule opened and dispersed with food or liquid. In the event of a missed dose, dosing can resume the next day.

Dosage may be altered by specialists to reflect the child’s current physical condition, symptoms or social demands. The patient should require no extra monitoring than already described in this guidance if dosage is adjusted by the specialist in this way.
As a child grows, the dose of dexamfetamine will need to be amended to ensure the treatment remains at steady state. A patient’s weight and height should be monitored as described under
“Ongoing monitoring”, and dosage may be increased if required as per the section above; “dosage and route of administration”. Increases in medication dose due to growth of the patient should be viewed as a patient’s treatment being “stable”.

Where a patient has been switched between medications (i.e. lisdexamfetamine to dexamfetamine) further monitoring may be required, as per specialist instruction.

Duration of treatment
Following an adequate treatment response, medication treatment for ADHD should be continued for as long as it remains clinically effective. This should be reviewed at least annually by the specialist.

In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. However, this scenario is not covered by the existing shared care protocol (RED classification) and arrangements will need to be made for patients approaching their 18th birthday to be referred back to their specialist in plenty of time to ensure continuity of on-going care by an adult ADHD specialist.

Monitoring Requirements and Responsibilities
Pre-treatment assessment to be performed by specialist and will include:

- Behavioural rating scales (e.g. SDQ, Conners’) and descriptive reports from parents and teachers, medical history, physical examination (including height and weight) and evaluation of cardiovascular status (including heart rate, blood pressure) as a baseline.
- For children where there is a first degree relative who has suffered from severe cardiac disease (e.g. myocardial infarction, arrhythmia) or sudden death of unknown cause before the age of 40 years, or in children who have a history of cardiac disease themselves, these patients should have further cardiac screening in the form of an ECG and echocardiogram. Cardiology expertise may be required in deciding if it is safe to start medication.

Ongoing monitoring – monitoring will be performed by the specialist within the first 3 months. Further physical monitoring will be performed by primary care (see below) and the results sent to the specialist for recording in the patients notes. Ongoing psychological response and assessment of continued need for lisdexamfetamine will be performed by the specialist at 3 months and 6 months and then at least annually.

If the child / young person fails to attend for physical monitoring, despite attempts to re-appoint, do not issue any further prescriptions, contact the patient/carer and inform the specialist. The patient should be informed of this policy when treatment begins.

<table>
<thead>
<tr>
<th>Ongoing monitoring</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Rate and Blood Pressure</td>
<td>Six monthly. Also before and after each dose change (note that increases in dose due to growth should be viewed as a patient being “stable” on their medication, and should require no extra monitoring). Compare with previous measurements.</td>
</tr>
<tr>
<td>Blood pressure centile reference tables for children and young people (age/sex) are available within the Nottingham University Hospitals Children’s Hospital Hypertension Guidelines (Jan 2019). Refer to paediatric hypertension specialist if blood pressure is consistently above the 95th centile for age and height.</td>
<td></td>
</tr>
<tr>
<td>Weight and appetite</td>
<td>Following initiation, at three months and six months, then:</td>
</tr>
</tbody>
</table>
Part of the Shared Care Protocol for ADHD in Children

**REVIEW DATE:** December 2022

**DATE APPROVED BY THE NOTTINGHAMSHIRE APC:** December 2019

---

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Every 3 months in children 10 years and under.</td>
</tr>
<tr>
<td></td>
<td>Every 6 months in children over 10 years and young people</td>
</tr>
<tr>
<td></td>
<td>Plot on a growth chart (<a href="http://www.rcpch.ac.uk/growthcharts">link</a>).</td>
</tr>
<tr>
<td></td>
<td>If weight loss or reduced weight gain this should be discussed with the specialist.</td>
</tr>
</tbody>
</table>

**Height**

- Six monthly.
- Plot on a growth chart.
- If growth is affected significantly this should be discussed with the specialist.

**Medication related side-effects***

- At each visit.

**Risk of diversion, misuse/abuse**

- At each visit

**ECG, LFTs, FBC**

- Not recommended unless there is a clinical indication.

---

**Explicit criteria for review and discontinuation of the medicine**

- Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a 1-month period. If paradoxical aggravation of symptoms or other intolerable adverse events occur, the dosage should be reduced or discontinued.
- In the event of treatment emergent psychotic or manic symptoms (hallucinations, delusional thinking, mania without prior history), consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate.
- In the presence of new onset or worsening seizures lisdexamfetamine should be discontinued.

For a full list of Side Effects refer to the BNF/cBNF or Summary of Product Characteristics (SPC).¹

**IF YOU ARE IN ANY DOUBT ABOUT ANY POTENTIAL ADVERSE REACTION, PLEASE CONTACT THE SPECIALIST TEAM.**

**Contraindications**

- Hypersensitivity to lisdexamfetamine
- Hypersensitivity to sympathomimetic amines or any of the excipients
- Concomitant use of MAOIs or within 14 days of MAOI treatment
- Hyperthyroidism or thyrotoxicosis
- Agitated states
- Symptomatic cardiovascular disease
- Advance arteriosclerosis
- Moderate to severe hypertension
- Glaucoma

**Precautions**

- Stimulants have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing the product. Use caution in prescribing to patients with a history of substance abuse or dependence.
- Sudden death has been reported in children and adolescents taking CNS stimulants, including those with structural cardiac abnormalities or other serious heart problems. Not for use in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medication.
• Stimulants may exacerbate symptoms of behaviour disturbance and thought disorder in patients with pre-existing psychotic disorders.
• Particular care should be taken in treating ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episodes in such patients.
• Treatment emergent psychotic or manic symptoms can be caused by stimulants at usual doses. If these occur, consider the potential role of the stimulant, and discontinuation of treatment may be appropriate.
• Stimulants have been associated with a slowing of weight gain and a reduction in attained height. Monitor growth during treatment with stimulants.
• Stimulants may lower the convulsive threshold in patients with prior history of seizure. In the presence of new onset or worsening seizures the medication should be discontinued.
• Due to reduced clearance in patients with severe renal insufficiency (GFR 15 to <30 mL/min/1.73 m² or CrCl <30 mL/min) the maximum dose should not exceed 50 mg/day.

Pregnancy and Breastfeeding

There are no adequate and well controlled studies of lisdexamfetamine in pregnant women. Dexamfetamine, the active metabolite of lisdexamfetamine, crosses the placenta. Lisdexamfetamine should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus.

Amfetamines are excreted in breast milk and should not be used in those who are breastfeeding.

Clinically relevant medicine interactions and their management

• Guanfacine plasma concentrations increased by lisdexamfetamine
• Venlafaxine. Conversion to the active metabolite o-desmethylvenlafaxine may be reduced by lisdexamfetamine.
• Agents that acidify urine increase urine excretion and decrease the half-life of amfetamine. Agents that alkalinise urine decrease urinary excretion and extend the half-life of amfetamine.
• Amfetamine should not be administered during or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) because it can increase the release of noradrenaline and other monoamines, causing severe headaches and other signs of hypertensive crisis.
• Amfetamines may decrease the effectiveness of guanethidine or other antihypertensives.
• Chlorpromazine blocks dopamine and noradrenaline receptors, thus inhibiting the CNS effects of amphetamines
• Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines
• Lithium carbonate inhibits the anorectic and stimulatory effects of amphetamines.
• Amfetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.

Information Given to Patient

• The specialist will provide relevant, written information to people with ADHD and their families and carers about diagnosis, assessment, support groups, self-help, psychological treatment, medication treatment and possible side-effects.
• The patient must be warned to report immediately any abdominal pain, unexplained nausea, malaise, darkening of the urine, jaundice, or suicidal thinking and self-harm to the GP.¹³
• Written information sheets on the medicines used in ADHD can be found at:
  https://www.choiceandmedication.org/nottinghamshirehealthcare/condition/attention-deficit-hyperactivity-disorder/
  http://www.rcpsych.ac.uk/healthadvice/parentsandyouthinfo/parentscarers/adhdhyperkineticdisorder.aspx
Patient Roles and Responsibilities
1. The patient will report any suspected adverse reactions to the GP for assessment.
2. The patient will report to their GP or specialist any new onset nausea, vomiting, abdominal discomfort, dark urine and jaundice as these could be adverse effects of lisdexamfetamine.
3. The patient will report to their GP or specialist signs of clinical worsening, suicidal thoughts or self-harming behaviour, irritability, psychotic symptoms, agitation, or depression as these can be adverse effects of lisdexamfetamine.
4. The patient will attend all follow-up appointments with GP and specialist. If they are unable to attend any appointments they should inform the relevant practitioner as soon as possible and arrange an alternative appointment.

Community Pharmacist Roles and Responsibilities
Community pharmacists are well placed to stress the value of a balanced diet, good nutrition and regular exercise for all patients with ADHD. Community pharmacists can offer support to help improve treatment adherence in patients with ADHD.

AUTHORS
Nick Sherwood – Mental Health Efficiencies Pharmacist (Nottinghamshire CCGs/Nottinghamshire Healthcare NHS Foundation Trust)
Dr Katherine Martin and Dr Amy Taylor (Community Paediatrics, Nottingham University Hospitals NHS Trust)
Dr Esther Corker (Community Paediatrician, Sherwood Forest Hospitals Trust)

References
1. Elvanse 20mg, 30mg, 40mg, 50mg, 60mg, 70mg capsules – Shire Pharmaceuticals ltd. Summary of product characteristics [07/2019] available at https://www.medicines.org.uk/emc/product/2979, accessed 02/12/2019
2. Attention deficit hyperactivity disorder: Diagnosis and management. NICE Clinical Guideline 87 (March 2018). Available: http://www.nice.co.uk/guidance/ng87
7. NUH Children’s Hospital Hypertension Guidelines (Jan 2019), (link)